Our Products

Advantage Multi® for Cats (imidacloprid + moxidectin)

Indications:
Advantage Multi® for Cats is a once-a-month topical solution for the prevention of heartworm disease, killing adult fleas, the treatment of flea infestations, the treatment and control of ear mite infestations and hookworm, round worms and whipworms infections in cats and kittens 9 weeks of age and older and ferrets that weigh at least 2 lbs.

Important Safety Information:
CAUTION: Federal (U.S.A.) law restricts Advantage Multi® for cats to use by or on the order of a licensed veterinarian. WARNINGS: Do not use on sick or debilitated cats or ferrets. Do not use on underweight cats (see ADVERSE REACTIONS). Do not use on cats less than 9 weeks of age or less than 2 lbs. body weight. Do not use on ferrets less than 2 lbs. body weight. PRECAUTIONS: Avoid oral ingestion. HUMAN WARNINGS: Children should not come in contact with the application site for 30 minutes after application.

WARNINGS: Do not use on sick, debilitated or underweight cats. (SEE ADVERSE REACTIONS). Do not use in cats less than 9 weeks of age or less than 2 lbs. body weight. PRECAUTIONS: Avoid oral ingestion. HUMAN WARNINGS: Children should not come in contact with the application site for 30 minutes after application.



Advantage Multi® for Dogs (imidacloprid + moxidectin)

Indications:
Advantage Multi® for Dogs is a once-a-month topical solution for the prevention of heartworm disease, the treatment of circulating microfilariae, killing adult fleas, the treatment of flea infestations, the treatment and control of sarcoptic mange, and the treatment and control of hookworm, round worms and whipworms infections in dogs and puppies that are at least 7 weeks of age and that weigh at least 3 lbs.

Important Safety Information:
CAUTION: Federal (U.S.A.) law restricts Advantage Multi® for dogs to use by or on the order of a licensed veterinarian. 

WARNING: DO NOT ADMINISTER THIS PRODUCT ORALLY. For the first 30 minutes after application ensure that dogs cannot lick the product from application sites on themselves or other treated animals. Children should not come in contact with the application sites for two (2) hours after application. (See Contraindications, Warnings, Human Warnings, and Adverse Reactions for more information.) CONTRAINDICATIONS: Do not use this product on cats.



advantus® (imidacloprid) Soft Chew

Indications: 
Use: advantus kills adult fleas and is indicated for the treatment of flea infestations on dogs and puppies 10 weeks of age and older and weighing 4 pounds or greater. 

Important Safety Information: 
Warnings: Not for human use. Keep this and all drugs out of reach of children. 

Do not give to puppies younger than 10 weeks of age or to dogs weighing less than 4 pounds. Do not give more than one soft chew a day. Keep out of reach of children. For complete directions for use and safety information see product label. 



Atopica® (cyclosporine capsules) USP MODIFIED

Indications: 
ATOPICA ^® is indicated for the control of atopic dermatitis in dogs weighing at least 4 pounds and at least 6 months of age. 

Important Safety Information:  
Do not use Atopica in dogs with a history of neoplasia, with a hypersensitivity to cyclosporine, or in reproducing dogs. Atopica is a systemic immunosuppressant that may increase susceptibility to infection and development of neoplasia. For use only in dogs. Capsules should not be broken or opened. Wear gloves during administration and wash hands after administration. Gastrointestinal problems and gingival hyperplasia may occur at the initial dose. Safety and effectiveness has not been established in dogs less than 6 months or 4 lbs. Use with caution in dogs with diabetes mellitus or renal insufficiency, and with drugs that affect the P-450 pathway. Killed vaccines are recommended. The most common adverse events are vomiting and diarrhea.  



Atopica^® for Cats (cyclosporine oral solution)  

Indications: 
ATOPICA^® for Cats (cyclosporine oral solution) USP MODIFIED is indicated for the control of feline allergic dermatitis as manifested by excoriations (including facial and neck), miliary dermatitis, eosinophilic plaques, and self-induced alopecia in cats at least 6 months of age and at least 3 lbs in body weight. 

Important Safety Information: 
Do not use in cats with a history or suspicion of malignant disorders, feline leukemia virus (FeLV) or feline immunodeficiency virus (FIV) infection, or hypersensitivity to cyclosporine. Atopica^® is a systemic immunosuppressant that may increase susceptibility to infection, development of neoplasia, and decrease response to vaccination. Persistent, progressive weight loss may result in hepatic lipidosis; monitoring of body weight is recommended. For use only in cats. Wash hands after administration. People with known hypersensitivity should avoid contact with Atopica^®. Do not use with other immunosuppressive agents. It is important for cats to avoid exposure to Toxoplasma gondii during treatment. Use with caution in cats with diabetes mellitus or renal insufficiency, and with drugs that affect the P-450 enzyme system. The most common adverse events were vomiting, weight loss, diarrhea or loss of appetite. Please speak with your veterinarian for advice. Please see product label for full prescribing information. 



Bexacat™ (bexagliflozin tablets)

Indication: 
Bexacat is indicated to improve glycemic control in otherwise healthy cats with diabetes mellitus not previously treated with insulin. 

Important Safety Information: 
Before using Bexacat, you must read the entire package insert, including the boxed warning. Cats treated with Bexacat may be at an increased risk for conditions called diabetic ketoacidosis or euglycemic diabetic ketoacidosis, both of which may result in death. It is critical that cats taking Bexacat be examined by a veterinarian promptly if sudden decreases in appetite or water consumption occur, or if weight loss, tiredness, vomiting, diarrhea, or weakness are seen. Discontinue Bexacat and call your veterinarian immediately if any of these occur as they could be signs of diabetic ketoacidosis or euglycemic diabetic ketoacidosis. Before giving Bexacat, be sure to talk with your veterinarian about any past illnesses your cat has had including if your cat has ever been on insulin, as cats that have been treated with insulin should not receive Bexacat. Do not use Bexacat if your cat has experienced pancreatitis, liver disease or reduced kidney function as serious side effects may occur. Bexacat is available by veterinary prescription only. Not for human use. Keep out of reach of children. Contact a physician immediately if swallowed accidentally. 



Canine Parvovirus Monoclonal Antibody

Safety information
Always read, understand and follow the label and use directions.



ChlorhexiDerm® 4% Shampoo 
CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.  For topical use on dogs, cats and horses.  Avoid contact with eyes.  Not for otic use.  If irritation develops, discontinue use and consult your veterinarian. 
WARNING: Keep out of reach of children. 



Claro® (florfenicol, terbinafine, mometasone furoate) Otic Solution 

Indications: 
CLARO is indicated for the treatment of otitis externa in dogs associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius). 

Important Safety Information: 
Do Not Use in Cats. 

CAUTION: Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian. 

CLARO should be administered by veterinary personnel. Wear eye protection when administering CLARO. (see Human Warnings, Precautions, Post-Approval Experience). Splatter may occur if the dog shakes its head following administration. 

Do not use in dogs with known tympanic membrane perforation (see Precautions). CLARO has been associated with rupture of the tympanic membrane. Reevaluate the dog if hearing loss or signs of vestibular dysfunction are observed during treatment. 

CLARO is contraindicated in dogs with known or suspected hyper-sensitivity to florfenicol, terbinafine hydrochloride, or mometasone furoate. 

Owners should be aware that adverse reactions may occur following administration of CLARO and should be instructed to observe the dog for signs such as ear pain and irritation, vomiting, head shaking, head tilt, incoordination, eye pain and ocular discharge (see Post-Approval Experience). Owners should also be informed that splatter may occur if the dog shakes its head following administration of CLARO which may lead to ocular exposure. Eye injuries, including corneal ulcers, have been reported in humans and dogs associated with head shaking and splatter following administration. Owners should be careful to avoid ocular exposure (see Precautions, Post-Approval Experience). 



Credelio® CAT (lotilaner)  

Indications: 
Credelio CAT kills adult fleas and is indicated for the treatment and prevention of flea infestations for one month in cats and kittens 8 weeks of age and older and weighing 2 pounds or greater. 

Credelio CAT is also indicated for treatment and control of black-legged tick infestations for one month in cats and kittens 6 months of age and older and weighing 2 pounds or greater. 

Important Safety Information: 
Lotilaner is a member of the isoxazoline class of drugs. This class has been associated with neurologic adverse reactions including tremors, incoordination, and seizures. Neurologic adverse reactions have been reported in cats receiving isoxazoline class drugs, even in cats without a history of neurologic disorders. Use with caution in cats with a history of neurologic disorders. The safety of Credelio CAT has not been established in breeding, pregnant and lactating cats. The effectiveness of Credelio CAT against black-legged ticks in kittens less than 6 months of age has not been evaluated. The most frequently reported adverse reactions are weight loss, rapid breathing and vomiting. For complete safety information, please see Credelio CAT product label or ask your veterinarian. 



Credelio® (lotilaner)  

Indications: 
Credelio kills adult fleas and is indicated for the treatment and prevention of flea infestations and treatment and control of tick infestations (lone star tick, American dog tick, black-legged tick, and brown dog tick) for one month in dogs and puppies 8 weeks and older and 4.4 pounds or greater. 

Important Safety Information: 
Lotilaner is a member of the isoxazoline class of drugs. This class has been associated with neurologic adverse reactions including tremors, incoordination, and seizures. Seizures have been reported in dogs receiving this class of drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. The safe use of Credelio in breeding, pregnant or lactating dogs has not been evaluated. The most frequently reported adverse reactions are weight loss, elevated blood urea nitrogen, increased urination, and diarrhea. For complete safety information, please see Credelio product label or ask your veterinarian. 



Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel) 

Indications: 
Credelio Quattro is indicated for the prevention of heartworm disease and the treatment and control of roundworm, hookworm* and tapeworm infections. Credelio Quattro kills adult fleas and is indicated for the treatment and prevention of flea infestations and the treatment and control of tick infestations for 1 month in dogs and puppies 8 weeks of age and older and weighing 3.3 pounds or greater. 

Important Safety Information: 
Lotilaner, an ingredient in Credelio Quattro, belongs to the isoxazoline class and has been associated with neurologic adverse reactions like tremors, ataxia, and seizures even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. Dogs should be tested for existing heartworm infections before Credelio Quattro administration as it is not effective against adult D. immitis. The safe use in breeding, pregnant, or lactating dogs has not been evaluated. The most frequently reported adverse reactions in clinical trials were vomiting and diarrhea. For complete safety information, please see Credelio Quattro product label or ask your veterinarian. 



Deramaxx® (deracoxib)  

Indications: 
DERAMAXX Chewable Tablets are indicated for the control of pain and inflammation associated with osteoarthritis in dogs. 

Important Safety Information: 
Not for use in humans. For use in dogs only. Keep this and all medications out of the reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. As with all drugs in this class, side effects involving the digestive system, kidneys or liver may occur. These are normally mild, but may be serious. Pet owners should discontinue therapy and contact their veterinarian immediately if side effects occur. All dogs should undergo a thorough history and physical examination before using DERAMAXX. Regular monitoring is recommended. Use with other NSAIDs or corticosteroids should be avoided. Please see the product insert for full prescribing information. 



Drontal® Plus (praziquantel/pyrantel pamoate/febantel) for Dogs

Indications:
Drontal Plus: This drug is indicated for removal of Tapeworms (Dipylidium caninum, Taenia pisiformis, Echinococcus granulosus, and removal and control of Echinococcus multilocularis). For removal of Hookworms (Ancylostoma caninum, Uncinaria stenocephala), Ascarids (Toxocara canis, Toxascaris leonina), and Whipworms (Trichuris vulpis) in dogs.

Important Safety Information:
Drontal Plus: CAUTION: Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.
DOSAGE: Not for use in puppies less than 3 weeks of age or weighing less than 2 lbs. CONTRAINDICATIONS: Do not use in pregnant animals. WARNING: Keep out of reach of children. For full safety information, see product label for tablets or product label for taste tabs.



Elura™(capromorelin oral solution)  

Indications: 
Elura is indicated for the management of weight loss in cats with chronic kidney disease. 

Important Safety Information: 
For oral use in cats only. Do not use in cats that have a hypersensitivity to capromorelin, or in cats with hypersomatotropism (acromegaly). Elura may increase serum glucose for several hours after dosing; use in cats with current or historical diabetes mellitus has not been evaluated and may not be appropriate. Use with caution in cats that may have cardiac disease, severe dehydration, or hepatic dysfunction. Elura has not been evaluated in cats younger than 5 months of age, or in breeding, pregnant or lactating cats. The most common adverse reactions included vomiting, hypersalivation, inappetence, behavior change and lethargy. Please see Elura product label for full Prescribing Information. 



Entyce® (capromorelin oral solution)  

Indications: 
For appetite stimulation in dogs. 

Important Safety Information: 
For use in dogs only. Do not use in dogs that have a hypersensitivity to capromorelin. Use with caution in dogs with hepatic dysfunction or renal insufficiency. The safe use of Entyce has not been evaluated in breeding, pregnant or lactating dogs. The most common adverse reactions included diarrhea, vomiting, elevated blood urea nitrogen, polydipsia, and hypersalivation. Please click here for full Prescribing Information. 



Galliprant® (grapiprant tablets)  

Indications: 
Galliprant is an NSAID that controls pain and inflammation associated with osteoarthritis in dogs. 

Important Safety Information: 
Not for use in humans. For use in dogs only. Keep this and all medications out of reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. Do not use in dogs that have a hypersensitivity to grapiprant. If Galliprant is used long term, appropriate monitoring is recommended. Concomitant use of Galliprant with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs. (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy. 



Interceptor® Plus (milbemycin oxime/praziquantel)  

Indications: 
Interceptor Plus prevents heartworm disease and treats and controls adult roundworm, hookworm, whipworm, and tapeworm infections in dogs and puppies 6 weeks or older and 2 pounds or greater. 

Important Safety Information: 
Treatment with fewer than 6 monthly doses after the last exposure to mosquitoes may not provide complete heartworm prevention. Prior to administration of Interceptor Plus, dogs should be tested for existing heartworm infections. The safety of Interceptor Plus has not been evaluated in dogs used for breeding or in lactating females. The following adverse reactions have been reported in dogs after administration of milbemycin oxime or praziquantel: vomiting, diarrhea, decreased activity, incoordination, weight loss, convulsions, weakness, and salivation. For complete safety information, please see Interceptor Plus product label or ask your veterinarian. 



K9 Advantix® II for Dogs 

Do not use K9 Advantix® II on cats. 



Nocita® (bupivacaine liposome injectable suspension) 

Indications: 
For single-dose infiltration into the surgical site to provide local postoperative analgesia for cranial cruciate ligament surgery in dogs. For use as a peripheral nerve block to provide regional postoperative analgesia following onychectomy in cats.  

Important Safety Information: 
NOCITA is for use in dogs and cats only. Do not administer concurrently with bupivacaine HCl, lidocaine or other amide local anesthetics. The safe use of NOCITA in dogs and cats with cardiac disease or with hepatic or renal impairment has not been evaluated. The safe use in dogs or cats younger than 5 months of age, that are pregnant, lactating, or intended for breeding has not been evaluated. The most common adverse reactions in dogs were discharge from incision, incisional inflammation and vomiting. The most common adverse reactions in cats were elevated body temperature and infection or chewing/licking at the surgical site. 



ONSIOR® (robenacoxib)  

Indications: 
ONSIOR Tablets for Cats is for the control of postoperative pain and inflammation associated with orthopedic surgery, ovariohysterectomy (spay) and castration (neuter) in cats greater than or equal to 5.5 pounds (2.5 kg) and greater than or equal to 4 months of age; for a maximum of 3 days.

Important Safety Information:
ONSIOR tablets for cats should only be given to cats. People should not take ONSIOR tablets. Keep ONSIOR tablets and all medication out of reach of children. Do not use in cats less than 5.5 lbs. or less than 4 months of age. Do not give ONSIOR if your cat has had an allergic reaction (such as hives, facial swelling, or red or itchy skin) to robenacoxib (the active ingredient in ONSIOR) or to aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs). Do not give Onsior with other NSAIDs (e.g., aspirin, meloxicam) or corticosteroids (e.g., prednisone). ONSIOR tablets should only be given once a day and for no longer than 3 days. ONSIOR tablets may cause some side effects in individual cats. These are normally mild, but serious side effects have been reported in cats taking NSAIDs including ONSIOR tablets. Serious side effects can result in death. It is important to stop the medication and contact your veterinarian immediately if your cat appears to be uncomfortable. Possible side effects are decreased appetite, vomiting, diarrhea, changed stool color, change in drinking or urination, behavioral changes such as depression or restlessness. For complete safety information, please see ONSIOR product label or ask your veterinarian.



Profender® Topical Solution (emodepside/praziquantel) 

Indications:
PROFENDER Topical Solution is indicated for the treatment and control of hookworm infections caused by Ancy/ostoma tubaeforme (adults, immature adults, and fourth stage larvae), roundworm infections caused by Toxocara cati (adults and fourth stage larvae), and tapeworm infections caused by Dipylidium caninum (adults) and Taenia taeniaeformis (adults) in cats.

Important Safety Information:
CAUTION: Federal (U.S.A.) law restricts Profender® to use by or on the order of a licensed veterinarian. HUMAN WARNING: Children should not contact application site for twenty-four (24) hours while the product is being absorbed. PRECAUTIONS: The effectiveness of this product when used before bathing has not been evaluated. Use with caution in sick or debilitated cats. Oral ingestion or exposure should be avoided. 



quellin® (carprofen)  

Indications: 
quellin is indicated for the relief of pain and inflammation associated with osteoarthritis and for the control of postoperative pain associated with soft tissue and orthopedic surgeries in dogs. 

Important Safety Information:
CAUTION: Federal law restricts quellin®  to use by or on the order of a licensed veterinarian.  

WARNINGS: Keep quellin®  soft chew tablets out of reach of children. Not for human use. For use in dogs only. Do not use in cats. All dogs should undergo a thorough history and physical examination before initiation of NSAID therapy. Appropriate laboratory tests to establish hematological and serum biochemical baseline data prior to, and periodically during, administration of any NSAID should be considered.  

PRECAUTIONS: Carprofen is an NSAID, and as with others in that class, adverse reactions may occur with its use. The most frequently reported effects have been gastrointestinal signs. Events involving suspected renal, hematologic, neurologic, dermatologic and hepatic effects have also been reported.  

CONTRAINDICATIONS: Carprofen should not be used in dogs exhibiting previous hypersensitivity to carprofen.  



Tanovea® (rabacfosadine for injection)  

Indications: 
Tanovea is indicated for the treatment of lymphoma in dogs. 

Important Safety Information: 
Tanovea is not for use in humans. Keep out of reach of children. Do not come into direct contact with Tanovea. Wear chemotherapy-resistant gloves to prevent contact with feces, urine, vomit, and saliva of treated dogs for five days following treatment. Rabacfosadine is cytotoxic and may cause birth defects and affect female and male fertility. Pregnant women, those who may become pregnant, and nursing women should not handle, prepare, or administer the product. Tanovea is associated with life-threatening or fatal pulmonary fibrosis. Monitoring for signs of pulmonary dysfunction is recommended. Do not use in dogs with pulmonary fibrosis, a history of chronic pulmonary disease that could lead to fibrosis, or in breeds with a predisposition to this condition such as West Highland White Terriers. Use with caution in other terrier breeds. Do not use in dogs that are pregnant, lactating, or intended for breeding. Tanovea is associated with dermatopathies which can worsen with subsequent treatment; careful monitoring is recommended. Tanovea can cause neutropenia with nadir around seven days post-treatment. Dogs should be frequently monitored for evidence of neutropenia during treatment. Most common adverse reactions included diarrhea, decreased appetite, emesis, lethargy, weight loss and neutropenia. Please see the package insert for full prescribing information. 



Trifexis® (spinosad + milbemycin oxime)  

Indications:
Trifexis prevents heartworm disease. Trifexis kills fleas and prevents flea infestations, and treats and controls adult hookworm, roundworm and whipworm infections in dogs and puppies 8 weeks and older and 5 pounds or more.

Important Safety Information:
The use of ivermectin at higher than FDA-approved doses at the same time as Trifexis can result in serious side effects. Treatment with fewer than three monthly doses after the last exposure to mosquitoes may not provide complete heartworm prevention. Prior to administration of Trifexis, dogs should be tested for existing heartworm infection. Use with caution in breeding females. The safe use of Trifexis in breeding males has not been evaluated. Use with caution in dogs with pre-existing epilepsy. The most common adverse reactions reported are vomiting, decreased activity, itching, decreased appetite, and diarrhea. To ensure heartworm prevention, observe your dog for one hour after administration. If vomiting occurs within an hour of administration, redose with another full dose. Puppies less than 14 weeks of age may experience a higher rate of vomiting. For complete safety information, please see Trifexis product label or ask your veterinarian.



Quad Dewormer (praziquantel/pyrantel pamoate/febantel) Chewable Tablets for Dogs 
WARNING: Keep out of reach of children. For complete directions for use and safety information see product label. 



Tapeworm Dewormer (praziquantel tablets) for Cats 
Not intended for use in kittens less than six (6) weeks of age. For complete directions for use and safety information see product label. 
WARNING: Keep out of reach of children. Not for human use. 

 

Tapeworm Dewormer (praziquantel tablets) for Dogs 
Not intended for use in puppies less than four (4) weeks of age. For complete directions for use and safety information see product label. 
WARNING: Keep out of reach of children. Not for human use. 



T8 Keto® Flush 
CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.  For topical use on dogs, cats and horses.  Avoid contact with eyes.  If eye contact occurs or skin irritation develops, rinse thoroughly with water, discontinue use and consult your veterinarian.  Available through licensed veterinarians. WARNINGS: Keep out of reach of children.  Not for human use. 

Zenrelia™ (ilunocitinib tablets)

INDICATIONS

Zenrelia is a prescription medication used to control itching and inflammation associated with skin allergies for dogs over 12 months of age.

IMPORTANT SAFETY INFORMATION

See package insert including the Boxed Warning. For full prescribing information speak with your veterinarian, call 1 888 545 5973 or visit www.elancolabels.com/us/zenrelia.

WARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease and inadequate immune response to vaccines. Dogs should not take Zenrelia for a time period before and after vaccination. Discuss your dog’s vaccine schedule with your veterinarian. Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Dogs should be monitored for the development of infections because Zenrelia may increase the chances of developing an infection. Neoplastic conditions (benign and malignant) were observed during clinical studies. The most common side effects were vomiting, diarrhea and tiredness. Zenrelia has not been tested in dogs used for breeding, pregnant, or lactating dogs and has not been evaluated in combination with glucocorticoids, cyclosporine, or other immune suppressive drugs.  

   

ZORBIUM™ (buprenorphine transdermal solution)

Indications: 
ZORBIUM is indicated for the control of postoperative pain associated with surgical procedures in cats. 

Important Safety Information: 
Before using ZORBIUM (buprenorphine transdermal solution), read the entire package insert including the Boxed Human Warning. 

ZORBIUM contains buprenorphine, an opioid that exposes humans to risks of misuse, abuse and addiction, which can lead to overdose and death. Use of buprenorphine may lead to physical dependence. The risk of abuse by humans should be considered when storing, administering and disposing of ZORBIUM. Serious, life-threatening or fatal respiratory depression may occur with accidental exposure to or with misuse or abuse of ZORBIUM. ZORBIUM should only be administered by veterinarians or veterinarian technicians who are trained in the handling of potent opioids. Accidental exposure to even one tube of ZORBIUM, especially in children, can result in a fatal overdose. 

ZORBIUM is for topical application in cats only. Do not come into direct contact with ZORBIUM. Wear impermeable latex or nitrile gloves, protective glasses and a laboratory coat when applying ZORBIUM. Following application to the cat, allow a minimum drying time of 30 minutes before direct contact with the application site. Do not administer to cats with a known hypersensitivity to buprenorphine hydrochloride, any inactive ingredients of ZORBIUM, or known intolerance to opioids. Do not apply ZORBIUM if the application site at the dorsal cervical area has diseased or injured skin, or to anatomic areas other than the dorsal cervical area because absorption characteristics may be different. Body temperature should be monitored postoperatively. Most common adverse reactions during anesthesia were hypothermia, hypotension and hypertension, and after anesthetic recovery were hypothermia, hyperthermia and sedation. The safe use of ZORBIUM has not been evaluated in debilitated cats; those with renal, hepatic, cardiac or respiratory disease; pregnant, lactating or breeding cats; in cats younger than four months old; or in cats <2.6 lbs. or >16.5 lbs.